202
Participants
Start Date
June 30, 2011
Primary Completion Date
October 31, 2013
Study Completion Date
March 31, 2015
dasatinib
GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Placebo
Matching Placebo
Vienna
Budapest
Budapest
Brussels
Blacktown
Liverpool
Tweed Heads
Leuven
Footscray
Parkville
Frankston
Pécs
Ghent
Győr
Bethlehem
Milan
Hamburg
Besançon
Udine
Boynton Beach
Tampa
Birmingham
Reggio Emilia
Saint-Priest-en-Jarez
Saint-Priest-en-Jarez
Angers
Cologne
Minneapolis
Lille
Ancona
Clermont-Ferrand
Wichita
Lyon
Tübingen
Paris
Zlín
Olomouc
Aurora
München
Albuquerque
Los Angeles
Clichy
Orange
San Francisco
Moscow
Craiova
Krasnodar
Voronezh
Cluj-Napoca
Kazan'
Chelyabinsk
Toronto
Toronto
Montreal
Pardubice
Prague
Dublin
Jelenia Góra
Lublin
Olsztyn
Bucharest
Hull
Chelmsford
Maidstone
Northwood
Sutton
Leeds
Edinburgh
Glasgow
Liverpool
London
London
Metropolitan Borough of Wirral
Salisbury
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY